Overcoming intractable diseases with “Regeneration-Inducing Medicine™”
September 18, 2025 | Timely Disclosure Information | temRIM Announces Proposal for Approval of Issuance of Stock Options to our Company’s Executive Officers, Employees, and External Collaborators |
---|---|---|
September 16, 2025 | IR News | Presentation Materials Financial Results for the Fiscal Year Ended July 31 2025 |
September 11, 2025 | Timely Disclosure Information | StemRIM Announces Fixed Details of the Issuance of Stock Options to Directors |
September 11, 2025 | Timely Disclosure Information | StemRIM Announces Fixed Details of the Issuance of Stock Options to Employees |
September 10, 2025 | Timely Disclosure Information | StemRIM Announces Issuance of Stock Acquisition Rights as Stock Options to Directors |
April 28, 2025 | NEWS | |
---|---|---|
April 25, 2023 | NEWS |
StemRIM is a biotechnology company aiming to develop a next generation of regenerative medicine, “Regeneration-Inducing Medicine™”. “Regeneration-Inducing Medicine™” is an innovative new class of medicine that induces functional regeneration of tissues and organs in the patient's body by maximizing the human body's innate ability of tissue repairing. We are pursuing research and development of new drugs based on a novel mechanism of action leading to recruitment of the patients’ own in-vivo stem cells to the damaged tissues for functional tissue regeneration without conventional cell-therapy approaches.
About Regeneration-Inducing Medicine™
Our Regeneration-Inducing Medicine™ overcomes many of the challenges faced by regenerative medicine and cell therapy—including high cost, difficulties in manufacturing and storage, and immune rejection upon transplantation—and offers new therapeutic options for diseases that have been difficult to treat with conventional therapies. If Regeneration-Inducing Medicine™ is brought to practical use, it is expected to greatly expand clinical applications and make a significant contribution to the future of healthcare.
We are currently advancing non-clinical development and clinical trials across multiple disease areas.